|
Suppliers for CAS
475108-18-0
|
Properties | | CAS |
475108-18-0 | | Formula |
C22H19ClN4O5 |
|
9 Registered suppliers
Amadis Chemical Company Limited
P.R.China
More details are to be found here
Hangzhou Keying Chem Co., Ltd.
P.R.China
More details are to be found here
Capot Chemical Co., Ltd.
P.R.China
More details are to be found here
Leap Chem Co., Ltd
P.R.China
Molecular Formula: C22H19ClN4O5
Molecular Weight: 454.86
Molecular Formula: C22H19ClN4O5 Molecular Weight: 454.86
More details are to be found here
Aea.ltd
P.R.China
Molecular Formula: C22H19ClN4O5 Molecular Weight: 454.86
More details are to be found here
Molecular Formula: C22H19ClN4O5 Molecular Weight: 454.86
More details are to be found here
BOC Sciences
USA
Description : Tivozanib is an orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death. VEGFR tyrosine kinases, frequently overexpressed by a variety of tumor cell types, play a key role in angiogenesis. Check for active clinical trials or closed clinical trials using this agent. - Molecular Weight :454.86306
- Purity :0.98
Molecular Formula : C22H19ClN4O5 Canonical SMILES : CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl
InChI :
InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28)
InChIKey :
SPMVMDHWKHCIDT-UHFFFAOYSA-N
Appearance :
Solid powder
Synonyms :
AV-951; AV951; AV 951; KRN951; KRN 951; KRN-951,
More details are to be found here
Chemos GmbH & Co. KG
Germany
Description : Tivozanib is an orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death. VEGFR tyrosine kinases, frequently overexpressed by a variety of tumor cell types, play a key role in angiogenesis. Check for active clinical trials or closed clinical trials using this agent. - Molecular Weight :454.86306
- Purity :0.98
Molecular Formula : C22H19ClN4O5 Canonical SMILES : CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl
InChI :
InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28)
InChIKey :
SPMVMDHWKHCIDT-UHFFFAOYSA-N
Appearance :
Solid powder
Synonyms :
AV-951; AV951; AV 951; KRN951; KRN 951; KRN-951,
More details are to be found here
Chemtour Biotech Co., Ltd
P.R.China
Description : Tivozanib is an orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death. VEGFR tyrosine kinases, frequently overexpressed by a variety of tumor cell types, play a key role in angiogenesis. Check for active clinical trials or closed clinical trials using this agent. - Molecular Weight :454.86306
- Purity :0.98
Molecular Formula : C22H19ClN4O5 Canonical SMILES : CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl
InChI :
InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28)
InChIKey :
SPMVMDHWKHCIDT-UHFFFAOYSA-N
Appearance :
Solid powder
Synonyms :
AV-951; AV951; AV 951; KRN951; KRN 951; KRN-951,
More details are to be found here
Santa Cruz Biotechnology, Inc.
USA
Description : Tivozanib is an orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death. VEGFR tyrosine kinases, frequently overexpressed by a variety of tumor cell types, play a key role in angiogenesis. Check for active clinical trials or closed clinical trials using this agent. - Molecular Weight :454.86306
- Purity :0.98
Molecular Formula : C22H19ClN4O5 Canonical SMILES : CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl
InChI :
InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28)
InChIKey :
SPMVMDHWKHCIDT-UHFFFAOYSA-N
Appearance :
Solid powder
Synonyms :
AV-951; AV951; AV 951; KRN951; KRN 951; KRN-951,
More details are to be found here
Detailed information on the suppliers of
|
details
details